“The board of directors in Photocure ASA has decided to convert a total of
607,500 conditional share options to unconditional share options”.
Hva gikk betingelsene ut på i forhold til betingningsløse aksje opsjoner?
Innløsningsprisen for disse opsjonene er kr. 145,27 per aksje. I note 7 i årsrapporten står det at opsjonene kan innløses over tre år med hhv 25%, 25% og 50% og at de faller bort etter fem år eller når noen slutter. Kan ikke se noen andre betingelser. Kan det bety at de nå kan innløse alle opsjonene i år 1 hvis f.eks. selskapet blir kjøpt opp?
Det er vel for å sikre administrasjonen greie fallskjermer ved oppkjøp tenker jeg…
Nei, ikke hvis det ikke fremgår av betingelsene hvordan et oppkjøp påvirker opsjonsprogrammet. Uten det er det bare 25 % som gjelder. Hensikten er å gjøre det attraktivt å bli i selskapet. Ved oppkjøp kommer ofte nye avtaler på bordet…
Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre 
Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.
Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:
- @Rodjer (159 likes)
- @Savepig (96 likes)
- @gabster (67 likes)
Resten av topp 10:
-
@kreinh (42 likes)
-
@tooeasy891 (28 likes)
-
@myk (26 likes)
-
@Fornybar (25 likes)
-
@rosk82 (23 likes)
-
@Quadruple (17 likes)
-
@Boykie (17 likes)
Gratulerer!
Norne Secuities
1Q22 Preview (report due May 11th) Share price: NOK 115.70 Target: NOK 140 (unchanged) Risk: Medium
COVID impact still to be felt, but major improvement likely in rest of ‘22 We keep our positive stance and NOK 140/sh TP on PHO ahead of the 1Q report on May 11th. Pandemic-related uncertainty is still there, and restrictions related to Omicron surge should have had a meaningful impact on growth. However, the pandemic seems to be fading and Photocure should be a big winner of the post pandemic reopening. Pandemic should still be visible in 1Q figures Photocure will release its 1Q22 report on May 11th . Our estimates stand at NOK 95m for revenues, which is flatQoQ, but up 16% YoY, as 1Q a year ago was massively affected by COVID. Still, the growth should be affected by Omicron variant spread and restrictions to hospitals prevailing in many areas. We estimate a negative EBITDA of NOK -1.3m, as the company prepares for postpandemic growth, which should come in the remainder of 2022 and long-term.
There were two worth-mentioning news since our last update on the stock. Photocure decided to change partner in Australia/New Zealand from Juno Pharmaceuticals to Endotherapeutics Group after Juno failed to generate any meaningful traction since 2015. Another news was related to observed Antitumour effect for Hexvix in pre-clinical studies. The news is positive even if these are very early studies, as they complement Hexivx’s already large body of knowledge of TURBT procedures and bladder cancer surveillance done with blue light using Hexvix making the proposition to patients more attractive. Long-term investment case intact We continue to view the PHO investment case standing on three growth legs: I. Short-term growth should come from the US with post-pandemic reopening. Blue Light Cystoscope installations should also pick up significantly now that Karl Storz launches new modernized equipment. II. In the medium-term, European organisation should deliver strong growth as proper sales efforts are being made in the existing Ipsen territories and new ones further turbocharged by the post-pandemic reopening. III. In the long-term, Photocure’s partner Asieris should launch Hexvix in China, which should further improve long-term growth prospects. Long-term growth prospects are furtherstrengthened by the potential approval of Cevira. Buy maintained at the same TP of NOK 140/sh We keep our Buy recommendation and NOK 140/sh TP ahead ofthe 1Q report next week. We strongly believe Photocure is going to be a big beneficiary from the post pandemic reopening, as access to hospitals improves and sales process is eased. Having also in mind the three-pillar growth story, we see plenty of share price appreciation triggers over the next quarters and years.
2 Likes
Resultatsmell for Photocure: Ned 47 millioner fra i fjor
Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre
Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.
Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:
- @Rodjer (144 likes)
- @roblar (42 likes)
- @gabster (41 likes)
Resten av topp 10:
-
@kreinh (37 likes)
-
@Savepig (36 likes)
-
@tooeasy891 (29 likes)
-
@Fornybar (17 likes)
-
@myk (15 likes)
-
@rosk82 (14 likes)
-
@Quadruple (13 likes)
Gratulerer!
Positive Data from the Danish National Patient Registry presented at the 2022 Nordic Urologisk Forening (NUF) Congress in Helsinki
9 Likes
Urologic Oncology: Seminars and Original Investigations
Available online 22 June 2022
In Press, Corrected ProofWhat are Corrected Proof articles?
Clinical-Bladder cancer
Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study
Highlights
•
Repeat instillation of
hexaminolevulinate (HAL) is safe.
Systemic adverse reactions from HAL are rare.HAL is safe following recent intravesical Bacillus Calmette-Guérin.
Abstract
Purpose
The therapeutic benefit of intravesical instillation of hexaminolevulinate (HAL) at the time of transurethral resection of bladder tumor (TURBT) has been demonstrated in multiple studies. The purpose of this study was to prospectively assess the safety of repeated administration of HAL from a phase III pre-trial planned analysis.
Materials and methods
All patients evaluated in the study received at least 1 dose of HAL at the time of office cystoscopy, and a subset of these patients (n = 103, 33.2%) received a second dose a few weeks later at the time of TURBT. Adverse events (AEs) were recorded, and the safety of repeat use of HAL was determined by comparing the proportion of patients with AEs considered causally related to HAL in the surveillance examination compared to the OR examination. Association between categorical variables was tested using Fisher’s Exact Test, and a P < 0.05 was considered statistically significant.
Results
HAL-related AEs were experienced by 6 patients (2.2%) during surveillance cystoscopy and 3 patients (3.4%) following TURBT (P = 0.76); 181 patients (59.5%) had prior exposure to HAL before enrolling in the study with no difference in the number of AEs when comparing prior exposure to HAL to no prior exposure (P = 0.76). Of the patients who previously received intravesical therapy, 8 (2.9%) had at least 1 AE during surveillance compared to 3 (9.7%) who had no prior intravesical therapy (P = 0.09).
Conclusions
Repeat use of HAL is safe even when administered within a few weeks of receiving a dose of intravesical therapy.
https://www.roche.com/investors/updates/inv-update-2022-06-16
Merlin skriver på HO:
"Roche launches human papillomavirus (HPV) self-sampling solution, expanding cervical cancer screening options
En slik screening kan bety voldsom etterspørsel etter Cevira, siden screeningen vil avsløre skjulte tilfeller. Dermed er Cevira mer aktuelt enn noensinne."